DrugPatentWatch Database Preview
Ipilimumab - Biologic Drug Details
» See Plans and Pricing
Summary for ipilimumab
| Tradenames: | 1 |
| Patents: | 236 |
| Applicants: | 1 |
| BLAs: | 1 |
| Suppliers: see list | 1 |
| Recent Clinical Trials: | See clinical trials for ipilimumab |
Recent Clinical Trials for ipilimumab
Identify potential brand extensions & biosimilar entrants
| Sponsor | Phase |
|---|---|
| Andrew J. Armstrong, MD | Phase 2 |
| Asan Medical Center | Phase 2 |
| Centre Leon Berard | Phase 3 |
Pharmacology for ipilimumab
| Mechanism of Action | CTLA-4-directed Antibody Interactions |
| Physiological Effect | Increased T Lymphocyte Activation |
Patent Text Search: US Patents for ipilimumab
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bristol Myers Squibb | YERVOY | ipilimumab | INJECTABLE; INJECTION | 125377 | 001 | 2011-03-25 | Start Trial | Medarex, Inc. (Princeton, NJ) | 2025-11-08 | RX | Orphan | search |
| Bristol Myers Squibb | YERVOY | ipilimumab | INJECTABLE; INJECTION | 125377 | 001 | 2011-03-25 | Start Trial | Gilead Sciences, Inc. (Foster City, CA) | 2026-07-21 | RX | Orphan | search |
| Bristol Myers Squibb | YERVOY | ipilimumab | INJECTABLE; INJECTION | 125377 | 001 | 2011-03-25 | Start Trial | Gilead Sciences, Inc. (Foster City, CA) | 2027-07-06 | RX | Orphan | search |
| Bristol Myers Squibb | YERVOY | ipilimumab | INJECTABLE; INJECTION | 125377 | 001 | 2011-03-25 | Start Trial | Bristol-Myers Squibb Company (Princeton, NJ) | 2028-08-01 | RX | Orphan | search |
| Bristol Myers Squibb | YERVOY | ipilimumab | INJECTABLE; INJECTION | 125377 | 001 | 2011-03-25 | Start Trial | Aegis Therapeutics LLC (San Diego, CA) | 2026-06-23 | RX | Orphan | search |
| Bristol Myers Squibb | YERVOY | ipilimumab | INJECTABLE; INJECTION | 125377 | 001 | 2011-03-25 | Start Trial | Gilead Sciences, Inc. (Foster City, CA) | 2026-07-07 | RX | Orphan | search |
| Bristol Myers Squibb | YERVOY | ipilimumab | INJECTABLE; INJECTION | 125377 | 001 | 2011-03-25 | Start Trial | Pfizer Inc. (New York, NY) | 2039-02-26 | RX | Orphan | search |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
International Patents for ipilimumab
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Canada | 2861335 | Start Trial |
| Japan | 2015110619 | Start Trial |
| New Zealand | 628528 | Start Trial |
| Singapore | 10201911240P | Start Trial |
| Japan | 2016513098 | Start Trial |
| Mexico | 2017012738 | Start Trial |
| European Patent Office | 2935248 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for ipilimumab
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| C1002 | France | Start Trial | PRODUCT NAME: COBICISTAT OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE OU UN SOLVATE ET LE DARUNAVIR OU SEL PHARMACEUTIQUEMENT ACCEPTABLE OU UN SOLVATE, EN PARTICULIER L'ETHANOLATE DE DARUNAVIR; REGISTRATION NO/DATE: EU/1/14/967 20141121 |
| 2015040,C2049506 | Lithuania | Start Trial | PRODUCT NAME: KOBICISTATAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/13/830/001 - 002 20130524 |
| 2015000080648 | Italy | Start Trial | PRODUCT NAME: COBICISTAT O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE(STRIBILD); AUTHORISATION NUMBER(S) AND DATE(S): C(2013)3210, 20130527 |
| C1000 | France | Start Trial | PRODUCT NAME: COBICISTAT OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE ET ATAZANAVIR OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE,EN PARTICULIER LE SULFATE D'ATAZANAVIR; REGISTRATION NO/DATE: EU/1/15/1025 20150715 |
| 353 | Luxembourg | Start Trial | PRODUCT NAME: COBICISTAT OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI ET ATAZANAVIR OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI, EN PARTICULIER LE SULFATE D'ATAZANAVIR; AUTHORISATION NUMBER AND DATE: EU/1/15/1025 |
| 0150046 | Estonia | Start Trial | PRODUCT NAME: KOBITSISTAAT; AUTHORISATION NO.: EMA/CHMP/596576/2017, AUTORISATION DATE: 20170914 |
| /2016 | Austria | Start Trial | PRODUCT NAME: COBICISTAT ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON UND TENOFOVIR ALAFENAMID ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON, INSBESONDERE TENOFOVIR ALAFENAMID FUMARAT; REGISTRATION NO/DATE: EU/1/15/1061 (MITTEILUNG) 20151123 |
| >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
